

# CITATION REPORT

List of articles citing

Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

DOI: 10.1016/s0140-6736(15)00349-9  
Lancet, The, 2015, 386, 1537-45.

**Source:** <https://exaly.com/paper-pdf/62548483/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
600	[In Process Citation]. <b>2015</b> , 156 Suppl 2, 3-24		
599	Hepatitis C [Therapie-Update. <b>2015</b> , 12, 7-16		
598	[Are HVC patients on hemodialysis really difficult to treat patients?]. <b>2015</b> , 22, 373		
597	Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine. <b>2015</b> , 16, 18033-53		8
596	Interferon-free combination therapies for the treatment of hepatitis C: current insights. <b>2015</b> , 7, 51-70		46
595	Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. <b>2015</b> , 6, 314-27		13
594	Towards eradication of hepatitis C virus from dialysis units. <i>Lancet, The</i> , <b>2015</b> , 386, 1514-5	40	14
593	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <b>2015</b> , 64, 1824-33		99
592	Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. <b>2015</b> , 47, 924-9		58
591	Ribavirin: Past, present and future. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 123-30	3.4	35
590	The Role of Direct Acting Anti-Virals in Chronic Hepatitis C Treatment-2016 Update. <b>2016</b> , 8,		
589	[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1]. <b>2016</b> , 67, 127-31		1
588	Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. <b>2016</b> , 10, 2119-27		6
587	Anti-Hepatitis Virus Agents. <b>2016</b> , 239-270		
586	Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. <b>2016</b> , 8, 61-8		9
585	Advances in hepatitis C therapy: What is the current state - what come's next?. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 139-47	3.4	75
584	Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland, Slovakia). <b>2016</b> , 2, 16-20		

583	Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. <b>2016</b> , 2016, 3852126	20
582	Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 1343-1353	3.4 12
581	Impact of grazoprevir and elbasvir in the treatment of hepatitis C virus-infected patients with chronic kidney disease and end-stage renal disease. <b>2016</b> , 7, 112-115	
580	Briefly Noted. <b>2016</b> , 29, 173-174	
579	Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. <b>2016</b> , 16, 1588-95	172
578	Perspectives on treating hepatitis C infection in the liver transplantation setting. <b>2016</b> , 21, 111-9	19
577	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. <b>2016</b> , 29, 999-1007	67
576	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. <b>2016</b> , 18, 22	13
575	Hepatitis C Therapy in Renal Patients: Who, How, When?. <b>2016</b> , 5, 313-27	9
574	Hepatitis C-A clinical review. <i>Journal of Medical Virology</i> , <b>2016</b> , 88, 1844-55	19.7 27
573	The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. <b>2016</b> , 36, 791-3	11
572	Genotype 1 hepatitis C virus and the pharmacist's role in treatment. <b>2016</b> , 73, 764-74	17
571	Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study. <b>2016</b> , 48, 2944-2946	19
570	Les nouveaux traitements de l'hépatite C. <b>2016</b> , 2016, 65-73	
569	Dialyseverfahren. <b>2016</b> , 11, 312-319	
568	Treatment of chronic hepatitis C virus infection in patients with end-stage renal disease on hemodialysis. <b>2016</b> , 8, 76-78	
567	Treatment of chronic hepatitis C in patients with cirrhosis. <b>2016</b> , 32, 143-51	10
566	Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS). <b>2016</b> , 61, 2087-93	16

565	Handbook of Hepatitis C. <b>2016</b> ,		1
564	Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem. <b>2016</b> , 37, 140-2		3
563	Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. <b>2016</b> , 32, 121-6		13
562	Validated UPLC/MS/MS assay for quantitative bioanalysis of elbasvir in rat plasma and application to pharmacokinetic study. <b>2016</b> , 1015-1016, 150-156		8
561	Hepatitis C Virus Infection in Chronic Kidney Disease. <b>2016</b> , 27, 2238-46		61
560	Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. <b>2016</b> , 39, 589-611		56
559	Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. <b>2016</b> , 65, 7-10		12
558	APASL consensus statements and recommendation on treatment of hepatitis C. <b>2016</b> , 10, 702-26		155
557	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 338-51	24.2	122
556	Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. <b>2016</b> , 15, 883-90		9
555	Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. <b>2016</b> , 9, 1413-1421		11
554	Treatment of hepatitis C in renal impairment and renal transplant. <b>2016</b> , 8, 438-448		
553	Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. <b>2016</b> , 9, 887-897		11
552	Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. <b>2016</b> , 41, 478-85		20
551	Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is Over. <b>2016</b> , 16, 1345-7		17
550	HCV and the kidney. <b>2016</b> , 36 Suppl 1, 28-33		25
549	Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population: The Dawn of a New Era. <b>2016</b> , 29, 5-6		8
548	Hepatitis C virus NS3/4a protease inhibitors. <b>2016</b> , 30, 84-92		67

547	Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. <b>2016</b> , 44, 728-37	10
546	Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. <b>2016</b> , 65, 1112-1119	41
545	New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). <b>2016</b> , 15, 85-100	15
544	Management of Post-Liver Transplant Recurrence of Hepatitis C. <b>2016</b> , 76, 1711-1717	3
543	Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. <b>2016</b> , 65, S82-S94	65
542	Second generation direct-acting antivirals - Do we expect major improvements?. <b>2016</b> , 65, S130-S142	28
541	Diagnostics in hepatitis C: The end of response-guided therapy?. <b>2016</b> , 65, S67-S81	19
540	Future landscape of hepatitis C research - Basic, translational and clinical perspectives. <b>2016</b> , 65, S143-S155	23
539	Hepatitis C und Nie ren er kran kun gen. <b>2016</b> , 11, 361-374	
538	Post-Liver Transplant Management of Hepatitis C. <b>2016</b> , 15, 167-177	
537	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. <b>2016</b> , 26, 408-434	32
536	[Expert recommendations: Hepatitis C and transplantation]. <b>2016</b> , 54, 665-84	6
535	Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities. <b>2016</b> , 8, 379-399	2
534	Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals. <b>2016</b> , 15, 285-290	0
533	Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. <b>2017</b> , 32, 2065-2071	37
532	Human Immunodeficiency Virus in Kidney Transplantation. <b>2016</b> , 36, 405-416	5
531	Vidal LL, et'al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 838-839	3-4
530	Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation. <b>2016</b> , 10, 248-56	2

529	Elbasvir/Grazoprevir. <b>2016</b> , 51, 665-686	5
528	Hepatitis C virus infection in maintenance hemodialysis patients: recommendations for diagnostics and treatment. <b>2017</b> , 39, 590-595	3
527	Management of hepatitis C genotype 4 in the directly acting antivirals era. <b>2016</b> , 3, e000112	10
526	Evolving therapies for hepatitis C virus in chronic kidney disease: the beginning of a new era. <b>2017</b> , 26, 129-135	4
525	Approved Antiviral Drugs over the Past 50 Years. <b>2016</b> , 29, 695-747	73 <sup>1</sup>
524	Management of HCV Infection. <b>2016</b> , 61-78	
523	[Chronic Hepatitis C - Therapeutic Options in 2016]. <b>2016</b> , 158 Suppl 1, 54-7	1
522	Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. <b>2016</b> , 22, 846-852	23
521	Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV. <b>2016</b> , 63 Suppl 1, S12-23	17
520	[Specific infections in organ transplantation]. <b>2016</b> , 57, 38-48	2
519	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. <b>2016</b> , 48, 251-261	11
518	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. <b>2016</b> , 150, 1590-1598	219
517	New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. <b>2016</b> , 89, 988-994	36
516	An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines. <b>2017</b> , 32, 32-35	8
515	Clinical Trial Watch: Reports from the Liver Meeting <sup>1</sup> , AASLD, San Francisco, November 2015. <b>2016</b> , 64, 1428-45	3
514	Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. <b>2016</b> , 12, 353-61	13
513	Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. <b>2016</b> , 10, 419-29	3
512	Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. <b>2016</b> , 51, 741-7	63

511	Elbasvir/Grazoprevir: First Global Approval. <b>2016</b> , 76, 617-24		29
510	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. <b>2016</b> , 25, 557-72		16
509	Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD. <b>2016</b> , 12, 5-6		4
508	Predictors of Deceased Donor Kidney Discard in the United States. <b>2017</b> , 101, 1690-1697		41
507	Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis. <b>2017</b> , 22, 706-711		4
506	Chronic hepatitis C and chronic kidney disease: Advances, limitations and uncharted territories. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 442-453	3-4	26
505	Detection, Reporting, and Treatment of Hepatitis C Infections Among Hemodialysis Patients. <b>2017</b> , 38, 493-494		2
504	Epidemiology update for hepatitis C virus and hepatitis B virus in end-stage renal disease in France. <b>2017</b> , 37, 820-826		16
503	Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment. <b>2017</b> , 37 Suppl 1, 19-25		12
502	Why and how to measure renal function in patients with liver disease. <b>2017</b> , 37 Suppl 1, 116-122		24
501	Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. <b>2017</b> , 11, 259-268		31
500	US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection. <b>2017</b> , 37, 317-326		8
499	Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. <b>2017</b> , 47, 1165-1173		12
498	No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel. <b>2017</b> , 73, 593-600		7
497	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. <b>2017</b> , 142, 83-122		111
496	Hepatitis C virus infection. <b>2017</b> , 3, 17006		224
495	Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. <b>2017</b> , 45, 267-272		11
494	Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. <b>2017</b> , 66, 736-745		53

493	Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. <b>2017</b> , 6, 147-163		9
492	Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. <b>2017</b> , 152, 1372-1382.e2		64
491	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <b>2017</b> , 49, 731-741		14
490	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. <b>2017</b> , 4, 174-185		31
489	Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4. <b>2017</b> , 77, 911-921		18
488	Direct-acting antivirals: the endgame for hepatitis C?. <b>2017</b> , 24, 31-37		62
487	Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 895-899	3-4	14
486	Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. <b>2017</b> , 2, 831-835		24
485	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. <b>2017</b> , 101, 933-937		13
484	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. <b>2017</b> , 47, 1429-1437		32
483	Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients. <b>2017</b> , 101, 974-979		12
482	Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation. <b>2017</b> , 101, 968-973		29
481	HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency. <b>2017</b> , 101, 924-932		3
480	Treating Hepatitis C in Patients with Renal Failure. <b>2017</b> , 35, 339-346		12
479	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. <b>2017</b> , 46, 46-55		14
478	Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. <b>2017</b> , 376, 2394-2395		251
477	Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients. <b>2017</b> , 101, 980-986		31
476	Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. <b>2017</b> , 12, 287-297		86



475	Recent advances in CKD and ESRD: A literature update. <b>2017</b> , 21, 11-18	0
474	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. <b>2017</b> , 2, 585-594	53
473	Antiviral treatment of hepatitis C in renal transplant patients - safety issues. <b>2017</b> , 16, 873-876	3
472	No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole. <b>2017</b> , 10, 360-365	7
471	Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. <b>2017</b> , 1, 248-255	20
470	Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis. <b>2017</b> , 101, 2088-2091	6
469	The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. <b>2017</b> , 17, 2790-2802	216
468	Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases. <b>2017</b> , 49, 1053-1055	
467	Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients. <b>2017</b> , 37, 158-163	4
466	Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. <b>2017</b> , 65, 64-72	23
465	Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. <b>2017</b> , 112, 828-832	34
464	Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost. <b>2017</b> , 136, 54-61	7
463	Sofosbuvir antiviral therapy in HCV patients with severe renal failure. <b>2017</b> , 40, 85-86	1
462	Sofosbuvir antiviral therapy in HCV patients with severe renal failure. <b>2017</b> , 40, 85-86	3
461	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. <b>2017</b> , 47, 1340-1345	21
460	Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. <b>2017</b> , 30, 865-873	49
459	Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective. <b>2017</b> , 43, 206-209	20
458	Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens. <b>2017</b> , 37, 687-697	8

457	Treating hepatitis C viral infection in patients with chronic kidney disease: When and how. <b>2017</b> , 9, 55-59		1
456	Grazoprevir/elbasvir combination therapy for HCV infection. <b>2017</b> , 10, 155-167		11
455	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. <b>2017</b> , 49, 561-575		11
454	The New Era of Hepatitis C: Therapy in Liver Transplant Recipients. <b>2017</b> , 21, 421-434		5
453	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. <b>2017</b> , 166, 637-648		383
452	Global epidemiology and burden of HCV infection and HCV-related disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 122-132	24.2	233
451	Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. <b>2017</b> , 47, 1147-1154		2
450	NS5A inhibitors for the treatment of hepatitis C infection. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 180-186	3.4	20
449	Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients. <i>Nefrologia</i> , <b>2017</b> , 37, 158-163	1.5	7
448	Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. <b>2017</b> , 37, 974-981		59
447	Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 268-279	3.4	12
446	Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 464-471	3.4	30
445	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <b>2017</b> , 47, 1127-1136		27
444	Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C. <b>2017</b> , 74, 1533-1540		7
443	Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. <b>2017</b> , 74, 1541-1544		4
442	Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	9
441	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. <b>2017</b> , 377, 1448-1455		277
440	Treatment of hepatitis C virus in advanced renal disease. <b>2017</b> , 10, 79-81		

439	Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends. <b>2017</b> , 28, 233-241	3
438	Direct-acting antivirals for chronic hepatitis C. <b>2017</b> , 9, CD012143	38
437	Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. <b>2017</b> , 12, 1615-1623	49
436	Contemporary Management of Hepatitis C in Patients with CKD. <b>2017</b> , 12, 1563-1565	2
435	Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician. <b>2017</b> , 21, 659-672	4
434	Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. <b>2017</b> , 21, 465-472	9
433	Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C. <b>2017</b> , 149, 375-382	2
432	Editorial: hepatitis C direct acting anti-viral agents and the kidney. <b>2017</b> , 46, 378-379	1
431	Treating hepatitis C virus in patients with chronic renal failure. <b>2017</b> , 2, 544-546	
430	Dual Organ Duel: The Hepatorenal Axis. <b>2017</b> , 24, 253-260	2
429	Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents. <b>2017</b> , 49, 1166-1169	2
428	Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. <b>2017</b> , 96, e7568	24
427	Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma. <b>2017</b> , 101, e12-e19	5
426	Direct-acting antivirals for chronic hepatitis C. <b>2017</b> , 6, CD012143	33
425	Hepatitis C Genotype 3 Infection: Pathogenesis and Treatment Horizons. <b>2017</b> , 21, 645-657	4
424	Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. <b>2017</b> , 7, e013620	23
423	Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C. <b>2017</b> , 149, 375-382	0
422	Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. <b>2017</b> , 2, 910-919	57

421	Recurrent Disease Following Liver Transplantation. <b>2017</b> , 1127-1142		
420	Treatment of Extrahepatic Manifestations of Hepatitis C Virus. <b>2017</b> , 21, 631-643		16
419	. <b>2017</b> , 159, 16		
418	Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis. <b>2017</b> , 51, 167-173		10
417	Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. <b>2017</b> , 25, 11		19
416	Allograft transmission of hepatitis C during the window period: Weighing the new risks and costs in the era of donor shortage. <b>2017</b> , 31, e13022		2
415	Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. <b>2017</b> , 152, 586-597		48
414	Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis. <b>2017</b> , 17, 819-823		4
413	Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. <b>2017</b> , 65, 439-450		59
412	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <b>2017</b> , 37, 5-18		62
411	Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 37-42	3-4	11
410	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. <b>2017</b> , 152, 164-175.e4		136
409	Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. <b>2017</b> , 68, 345-358		47
408	Hepatitis C and kidney disease: A narrative review. <b>2017</b> , 8, 113-130		27
407	The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. <b>2017</b> , 52, 520-533		64
406	Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. <b>2017</b> , 11, 152-160		11
405	EASL Recommendations on Treatment of Hepatitis C 2016. <b>2017</b> , 66, 153-194		821
404	Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. <b>2017</b> , 1, 757-764		4

403	Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. <b>2017</b> , 40, 531-541		9
402	Hepatitis C. <b>2017</b> , 628-698		
401	Treating Hepatitis C Infection in Patients With Chronic Kidney Disease: Our Options Have Improved Greatly. <b>2017</b> , 9, 403-410		
400	Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection. <b>2017</b> , 1, 148-152		1
399	Efficacy and safety of elbasvir and grazoprevir for chronic hepatitis C patients with chronic kidney disease. <b>2017</b> , 58, 678-680		1
398	Hepatitis B and C in Kidney Transplantation. <b>2017</b> ,		0
397	Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C. <b>2017</b> ,		
396	Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. <b>2017</b> , 11, 2131-2138		9
395	Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. <b>2017</b> , 13, 733-738		12
394	Treatment Options in Hepatitis C. <b>2017</b> , 114, 11-21		14
393	Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 180-190	3-4	11
392	Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study. <b>2017</b> , 17, 99		3
391	Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 722	4	24
390	Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies. <b>2017</b> , 4, ofx095		12
389	Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. <b>2017</b> ,		1
388	Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program. <b>2017</b> , 16, 71-76		0
387	Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. <b>2017</b> , 16, 207-214		17
386	Glecaprevir + pibrentasvir for treatment of hepatitis C. <b>2018</b> , 19, 413-419		12

385	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <b>2018</b> , 67, 2113-2126	18
384	Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges. <b>2018</b> , 29, 933-936	
383	Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. <b>2018</b> , 48, 746-756	7
382	Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. <b>2018</b> , 63, 1334-1340	27
381	Treatment of early stage chronic hepatitis C virus infection. <b>2018</b> , 11, 519-524	4
380	[Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects]. <b>2018</b> , 59, 401-409	1
379	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. <b>2018</b> , 50, 569-583	13
378	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. <b>2018</b> , 37, 17-39	122
377	Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. <b>2018</b> , 47, 1511-1522	23
376	Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. <b>2018</b> , 38, 2137-2148	23
375	Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. <b>2018</b> , 22 Suppl 1, S71-S80	8
374	Treatment and management options for the hepatitis C virus infected kidney transplant candidate. <b>2018</b> , 22 Suppl 1, S36-S44	4
373	Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. <b>2018</b> , 43, 594-605	14
372	Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. <b>2018</b> , 2, 595-606	18
371	Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. <b>2018</b> , 12, 133-142	14
370	Host-targeting therapies for hepatitis C virus infection: current developments and future applications. <b>2018</b> , 11, 1756284818759483	22
369	EASL Recommendations on Treatment of Hepatitis C 2018. <b>2018</b> , 69, 461-511	1079
368	Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). <b>2018</b> , 61, 4052-4066	28

367	End-Stage Renal Disease and Treatment of Hepatitis C Virus Infection. <b>2018</b> , 17, 78-82	1
366	Business of dialysis and the role of the medical director. <b>2018</b> , 31, 177-182	1
365	Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. <b>2018</b> , 35, 117-122	10
364	Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <b>2018</b> , 93, 545-559	88
363	Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations". <b>2018</b> , 38 Suppl 1, 28-33	28
362	Managing hepatitis C in patients with the complications of cirrhosis. <b>2018</b> , 38 Suppl 1, 14-20	9
361	Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. <b>2018</b> , 38 Suppl 1, 7-13	91
360	Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. <b>2018</b> , 102, e163-e170	29
359	The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. <b>2018</b> , 53, 679-688	34
358	HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES. <b>2018</b> , 38, 1411-1417	7
357	Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. <b>2018</b> , 43, 321-329	4
356	High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. <b>2018</b> , 38, 1395-1401	8
355	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <b>2018</b> , 48, 529-538	14
354	Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. <b>2018</b> , 93, 560-567	38
353	Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. <b>2018</b> , 58, 666-673	13
352	Treatment of hepatitis C in special populations. <b>2018</b> , 53, 591-605	20
351	A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. <b>2018</b> , 40, 719-732.e1	3
350	Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. <b>2018</b> , 113, 863-871	2

349	Timing of hepatitis C virus infection treatment in kidney transplant candidates. <b>2018</b> , 22 Suppl 1, S61-S70	8
348	Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. <b>2018</b> , 22 Suppl 1, S8-S21	19
347	Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. <b>2018</b> , 22 Suppl 1, S22-S35	6
346	Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. <b>2018</b> , 22 Suppl 1, S81-S96	23
345	Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates. <b>2018</b> , 22 Suppl 1, S45-S52	7
344	Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents. <b>2018</b> , 22 Suppl 1, S53-S60	3
343	The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development. <b>2018</b> , 17, 97-104	
342	Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3. <b>2018</b> , 40, 704-718.e6	5
341	'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. <b>2018</b> , 41, 363-370	5
340	Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir. <b>2018</b> , 43, 509-531	3
339	New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 7-9	7-4 1
338	Treatment Choices for Hepatitis C in Patients with Kidney Disease. <b>2018</b> , 13, 793-795	5
337	Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study. <b>2018</b> , 7, 44-52	21
336	Real-world challenges for hepatitis C virus medications: a critical overview. <b>2018</b> , 44, 143-160	14
335	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <b>2018</b> , 53, 119-128	40
334	Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. <b>2018</b> , 31, 1-13	11
333	Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. <b>2018</b> , 183, 118-126	105
332	Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States. <b>2018</b> , 102, 454-460	25



331	Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study. <b>2018</b> , 22, 217-221		14
330	When and how can nephrologists treat hepatitis C virus infection in dialysis patients?. <b>2018</b> , 31, 26-36		8
329	Current and future challenges in HCV: insights from an Italian experts panel. <b>2018</b> , 46, 147-163		3
328	Clinical trials: Treatment of HCV-infected patients with advanced kidney disease. <b>2018</b> , 14, 6-8		1
327	Hepatitis C virus genotyping of organ donor samples to aid in transplantation of HCV-positive organs. <b>2018</b> , 32, e13172		8
326	Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. <b>2018</b> , 68, 814-826		28
325	Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. <b>2018</b> , 68, 904-911		30
324	Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. <b>2018</b> , 67, 2430-2448		28
323	Management of Chronic Hepatitis C in End-stage Renal Disease. <b>2018</b> , 52, 287-294		2
322	Race but not Hepatitis C co-infection affects survival of HIV individuals on dialysis in contemporary practice. <b>2018</b> , 93, 706-715		10
321	Efficacy and safety of 12 weeks of elbasvir–grazoprevir–ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 457-464	3-4	23
320	Safety, Tolerability, and Associated Side Effects of Direct- Acting Antivirals. <b>2018</b> ,		
319	Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients. <b>2018</b> , 102, 1179-1187		5
318	Management of hepatitis C in a patient undergoing solid organ (kidney) transplant. <b>2018</b> , 3, 231-237		
317	2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. <i>Clinical and Molecular Hepatology</i> , <b>2018</b> , 24, 169-229	6.9	24
316	Interferon-Free Regimen for Hepatitis C: Insight and Management. <b>2018</b> , 28, 373-384		
315	Managing diabetes and liver disease association. <b>2018</b> , 19, 166-179		11
314	Resistance-Associated Substitutions/Variants Correlate to Therapeutic Outcomes of Novel Direct-Acting Antivirals in Different HCV Genotype Treated Individuals. <b>2018</b> ,		0

313	Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. <b>2018</b> , 11, 1993-2000		6
312	Expert opinion on the management of renal manifestations of chronic HCV infection. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 57-67	1.6	2
311	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <b>2018</b> , 41, 597-608		10
310	Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. <b>2018</b> , 2, 300-306		3
309	Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?. <b>2018</b> , 11, 1756284818812358		8
308	Hepatitis C Virus in the Modern Direct-Acting Antiviral Era: Where Have All the Special Populations Gone?. <b>2018</b> , 12, 143-149		
307	Hepatitis C virus infection and chronic renal disease: A review. <b>2018</b> , 37, 492-503		9
306	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <b>2018</b> , 41, 597-608		
305	Hepatitis C virus infection. <b>2018</b> , 1, 46-49		
304	Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir. <b>2018</b> , 48, 914-923		8
303	Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection. <b>2018</b> , 13, 1471-1478		15
302	Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life. <b>2018</b> , 2018, 8953581		6
301	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2018</b> , 13, 1129-1146		2
300	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2018</b> , 31, 685-712		3
299	Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence. <b>2018</b> , 12, 2749-2756		4
298	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2018</b> , 50, 1133-1152		2
297	Autoimmune Kidney Diseases Associated with Chronic Viral Infections. <b>2018</b> , 44, 675-698		4
296	Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis. <b>2018</b> , 7,		10

295	Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. <b>2018</b> , 159, 143-152	15
294	Managing hepatitis C therapy failures and chronic kidney disease. <b>2018</b> , 11, 1135-1142	4
293	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. <b>2019</b> , 34, 12-21	17
292	Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. <b>2018</b> , 285, 55-71	8
291	KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. <b>2018</b> , 8, 91-165	95
290	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <b>2018</b> , 67, 1477-1492	344
289	Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. <b>2018</b> , 20, 18	9
288	The Mexican consensus on the treatment of hepatitis C. <b>2018</b> , 83, 275-324	9
287	Transplantation Opportunities of Hepatitis C Virus-Seropositive Patients on the Kidney Waiting List. <b>2018</b> , 50, 3181-3184	
286	Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. <b>2018</b> , 48, 35-43	19
285	[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. <b>2018</b> , 56, 756-838	24
284	The road map toward an hepatitis C virus-free transplant population. <b>2018</b> , 18, 2409-2416	2
283	Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube. <b>2018</b> , 43, 730-732	9
282	Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation. <b>2018</b> , 18, 2483-2495	8
281	Hepatitis C Virus Infection in ESKD Patients. <b>2018</b> , 13, 1735-1737	1
280	No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy. <b>2018</b> , 11, 562-572	2
279	Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. <b>2018</b> , 33, 670-678	6
278	Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. <b>2018</b> , 169, 273-281	139

277	Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. <b>2018</b> , 169, 214-223		20
276	No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy. <b>2018</b> , 11, 553-561		3
275	Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 593-603	1.6	14
274	Treatment of Hepatitis C Virus Infection in Dialysis Patients. <b>2018</b> , 196, 119-122		3
273	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. <b>2018</b> , 168, 533-540		180
272	Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease-Author's reply. <b>2018</b> , 48, 227		
271	Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. <b>2018</b> , 69, 1178-1187		70
270	Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease. <b>2018</b> , 48, 226-227		1
269	Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. <b>2018</b> , 4, 55		2
268	Hepatitis C Virus Treatment in Non-Liver Organ Transplantation Programs. <b>2018</b> , 17, 105-110		
267	Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study. <b>2018</b> , 43, 707-713		7
266	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <b>2018</b> , 94, 206-213		12
265	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. <b>2018</b> , 10, 33-42		3
264	Management of Viral Hepatitis in Solid Organ Transplant Recipients. <b>2018</b> , 32, 635-650		7
263	The Mexican consensus on the treatment of hepatitis C. <b>2018</b> , 83, 275-324		
262	Hepatitis C virus infection in patients with end-stage renal disease. <b>2018</b> , 22, 297-307		8
261	Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1501-1506	3-4	13
260	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. <b>2018</b> , 11, 1119-1135		5

259	Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1270-1279	3.4	24
258	Hepatitis C. <b>2018</b> , 436-467		
257	Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be. <b>2018</b> , 94, 18-21		1
256	Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation. <b>2018</b> , 48, 1045-1054		6
255	Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. <b>2018</b> , 102, 2088-2095		26
254	Hepatitis C virus infection and the kidney. <b>2018</b> ,		1
253	Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. <b>2019</b> , 49, 256-263		10
252	Epidemiological Survey of Patients With Hemodialysis Complicated by Hepatitis C in Japan. <b>2019</b> , 23, 44-48		4
251	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <b>2019</b> , 54, 78-86		14
250	Prevention Strategies for Hepatocellular Carcinoma. <b>2019</b> , 255-289		1
249	Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. <b>2019</b> , 35, 161-170		31
248	The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir. <b>2019</b> , 20, 631-641		1
247	Co-encapsulation of enzyme and tricyanofuran hydrazone into alginate microcapsules incorporated onto cotton fabric as a biosensor for colorimetric recognition of urea. <b>2019</b> , 142, 199-206		41
246	Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. <b>2019</b> , 34 Suppl 1, 5-15		1
245	Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study. <b>2019</b> , 19, 3345-3355		11
244	Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1249-1256	3.4	10
243	Nephro Update Europe 2018. <b>2019</b> , 5, 173-181		1
242	Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. <i>Pathogens</i> , <b>2019</b> , 8,	4.5	14

241	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , <b>2019</b> , 58, 943-947	1.1	4
240	Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1404-1412	3-4	11
239	A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment. <b>2019</b> , 1, 200-206		2
238	Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD. <b>2019</b> , 1, 150-152		
237	Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older. <b>2019</b> , 5, 2333721418817398		2
236	Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. <b>2019</b> , 75, 665-675		7
235	Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. <b>2019</b> , 5, e416		23
234	Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. <b>2019</b> , 4, 245-256		5
233	Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants. <b>2019</b> , 8, 952-961		0
232	Viral Hepatitis: Chronic Hepatitis C. <b>2019</b> ,		1
231	Treatment of Hepatitis C Virus-Infected Patients with Renal Failure. <b>2019</b> , 97-107		
230	Infectious Diseases in Solid-Organ Transplant Recipients. <b>2019</b> ,		
229	Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients. <b>2019</b> , 2019, 4674560		12
228	Infections in Kidney and Pancreas Transplantation. <b>2019</b> , 73-109		1
227	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. <b>2019</b> , 58, 1237-1263		34
226	Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation. <b>2019</b> , 21, e13090		2
225	Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation. <b>2019</b> , 43, 913-920		3
224	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <b>2019</b> , 51, 915-921		8

223	Hepatitis C and kidney transplant: The eradication time of the virus has arrived. <i>Nefrologia</i> , <b>2019</b> , 39, 458-472	1.5	3
222	Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. <b>2019</b> , 33, e13514		33
221	Non-immunological complications following kidney transplantation. <b>2019</b> , 8,		11
220	Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease. <b>2019</b> , 26, 41-50		3
219	Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. <b>2019</b> , 16, 34		21
218	Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. <b>2019</b> , 70, 831-838		11
217	High prevalence of occult hepatitis C infection in predialysis patients. <i>World Journal of Hepatology</i> , <b>2019</b> , 11, 109-118	3-4	5
216	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <b>2019</b> , 34, 1977-1983		3
215	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <b>2019</b> , 54, 641-649		12
214	Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. <b>2019</b> , 12, 502-508		0
213	HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. <b>2019</b> , 6, 20		7
212	Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach. <b>2019</b> , 41, 539-549		5
211	Hepatitis C Virus (HCV) Infection: in 'Special Situations. <b>2019</b> , 470-489		
210	Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection. <b>2019</b> , 34, 1597-1603		10
209	Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	5
208	Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait list. <b>2019</b> , 23, E78-E82		1
207	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <b>2019</b> , 171, 496-504		11
206	National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. <b>2019</b> , 30, 1939-1951		43

205	Factors influencing hepatitis C cure in the era of direct-acting antivirals. <b>2019</b> , 42 Suppl 1, 1-7		1
204	Optimisation in the multidisciplinary approach to patients with hepatitis C in the era of direct-acting antivirals. <b>2019</b> , 42 Suppl 1, 8-13		
203	Importance of adherence to treatment with direct-acting antivirals in hepatitis C. <b>2019</b> , 42 Suppl 1, 14-19		2
202	Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 534-539	2.2	1
201	The Evolution of Clinical Trials for Hepatitis C. <b>2019</b> , 187-235		
200	Development of ZEPATIER <sup>®</sup> . <b>2019</b> , 369-407		1
199	Real-World Evidence and Hepatitis C. <b>2019</b> , 411-427		
198	Liver Disease Among Renal Transplant Recipients. <b>2019</b> , 539-565		
197	Hepatitis C and kidney transplant: The eradication time of the virus has arrived. <b>2019</b> , 39, 458-472		
196	Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. <b>2019</b> , 98, e16254		8
195	Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. <b>2019</b> , 5, e419		4
194	Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. <b>2019</b> , 10, e00007		10
193	Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. <b>2019</b> , 11, 617-628		1
192	Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy. <b>2019</b> , 32, 141-151		3
191	Hemodialysis-Associated Infections. <b>2019</b> , 389-410.e8		4
190	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 117-138		5
189	Evaluating CKD/ESRD patient with hepatitis C infection: How to interpret diagnostic testing and assess liver injury. <b>2019</b> , 32, 119-126		2
188	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. <b>2019</b> , 32, 135-140		3



187	Treating hepatitis C virus in dialysis patients: How, when, and why?. <b>2019</b> , 32, 152-158		3
186	ESRD patients coinfectd with human immunodeficiency virus and Hepatitis C: Outcomes and management challenges. <b>2019</b> , 32, 159-168		3
185	Hepatitis C virus and the kidney. <b>2019</b> , 15, 73-86		32
184	The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 329-336	3-4	7
183	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. <b>2019</b> , 4, 257-266		7
182	Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort. <b>2019</b> , 13, 89-93		0
181	Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function. <b>2019</b> , 4, 191-193		1
180	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. <b>2019</b> , 13, 103-109		19
179	The association of hepatitis C infection with the onset of CKD and progression into ESRD. <b>2019</b> , 32, 108-118		12
178	Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease. <b>2019</b> , 32, 187-195		12
177	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2019</b> , 47, 141-168		
176	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 55-64	3-4	16
175	Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. <b>2020</b> , 56, 105571		11
174	Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. <b>2020</b> , 97, 193-201		23
173	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. <i>Nefrologia</i> , <b>2020</b> , 40, 46-52	1.5	2
172	Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. <b>2020</b> , 18, 2158-2167		5
171	Liver Disease and Chronic Kidney Disease. <b>2020</b> , 863-882		
170	Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. <b>2020</b> , 10,		7

169	HCV in the haemodialysis population: Treat now or later?. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 233-234	3,4	1
168	Overview of hepatitis C infection, molecular biology, and new treatment. <b>2020</b> , 13, 773-783		16
167	Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. <b>2020</b> , 35, 1238-1246		7
166	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. <b>2020</b> , 174, 104698		6
165	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <b>2020</b> , 52, 190-198		6
164	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <b>2020</b> , 40, 1032-1041		23
163	Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. <b>2020</b> , 40, 1042-1051		7
162	Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. <b>2020</b> , 40, 797-805		11
161	Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. <b>2020</b> , 4, 1206-1217		1
160	Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. <b>2020</b> , 58, 1110-1131		3
159	Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation. <b>2020</b> , 21, 473		2
158	Current state of kidney transplantation in patients with HIV, hepatitis C, and hepatitis B infection. <b>2020</b> , 34, e14048		1
157	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial. <b>2020</b> , 12, 61-68		1
156	The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C. <b>2020</b> , 3, 251-262		
155	Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. <b>2021</b> , 36, 1867-1871		1
154	EASL recommendations on treatment of hepatitis C: Final update of the series. <b>2020</b> , 73, 1170-1218		237
153	Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial. <b>2020</b> , 4, 1065-1073		0
152	Viral hepatitis in patients on hemodialysis. <b>2020</b> , 33, 254-262		0

151	. 2020,	0
150	Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. <b>2020</b> , 36, 1325-1332	3
149	Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. <b>2021</b> , 54, 588-595	2
148	Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. <b>2020</b> , 52, 815-822	4
147	Direct acting antiviral HCV treatment does not influence renal function. <b>2020</b> , 99, e20436	5
146	Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. <b>2020</b> , 5, 918-926	9
145	Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1222-1233	3-4 0
144	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. <b>2020</b> , 40, 46-52	1
143	Hepatitis c virus and chronic kidney disease. <b>2020</b> , 14, 579-590	5
142	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <b>2020</b> , 10, 9180	2
141	An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease. <b>2020</b> , 15, 17-20	2
140	Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 505-513	3-4 2
139	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. <b>2020</b> , 7, ofaa040	11
138	A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants. <b>2020</b> , 12, 1-11	2
137	Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation. <b>2020</b> , 230, 853-861.e3	3
136	Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. <b>2020</b> , 21, 21	9
135	The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. <b>2020</b> , 35, 1590-1594	11
134	Therapeutic management of HIV-infected patients with chronic kidney disease. <b>2020</b> , 33, 699-713	5

133	Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. <b>2020</b> , 50, 791-816	30
132	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <b>2020</b> , 119, 1135-1157	34
131	Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. <b>2020</b> , 42, 377-380	
130	KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 75, 665-683	9
129	Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection. <b>2020</b> , 9, 355-365	2
128	Hepatitis C and Treatment in Patients with Chronic Kidney Disease. <b>2021</b> , 67, 101017	0
127	Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. <b>2021</b> , 36, 1152-1158	4
126	Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies. <b>2021</b> , 36, 1126-1135	1
125	INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. <b>2021</b> , 11, 354-386	1
124	Hepatitis C viraemic organs in solid organ transplantation. <b>2021</b> , 74, 716-733	6
123	Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. <b>2021</b> , 36, 42-50	4
122	Current Management of Patients with HCV Genotype 4. <b>2021</b> , 119-127	
121	Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. <b>2021</b> , 14, 289-301	6
120	Management of Patients with Renal Impairment: Direct-Acting Antivirals and Renal Function. <b>2021</b> , 175-190	
119	Available Agents: Contraindications and Potential Drug-Drug Interactions. <b>2021</b> , 43-74	
118	Current Management of Patients with HCV Genotype 1. <b>2021</b> , 75-82	
117	Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients. <b>2021</b> , 3, 160-164	
116	Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. <b>2021</b> , 10,	0

115	Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
114	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'Liver Network Activity' (LINA) cohort update results. <b>2021</b> , 15, 1057-1063		
113	Impact of antiviral therapy with direct acting antiviral agents (DAAs) on kidney disease in patients with chronic hepatitis C. <b>2021</b> , 67, 244-253		2
112	Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. <b>2021</b> ,		1
111	Poor management of hepatitis C infection will cause serious issues for patients with advanced chronic kidney disease. <b>2021</b> , 14, 87-89		
110	Blinding in Clinical Trials for Chronic Liver Diseases. <b>2021</b> , 41, 163-171		0
109	Breakthroughs and challenges in the management of pediatric viral hepatitis. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 2474-2494	5.6	1
108	Progress in hepatitis C virus management in chronic kidney disease. <b>2021</b> , 30, 493-500		
107	Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease.. <i>Kidney360</i> , <b>2021</b> , 2, 1316-1325	1.8	
106	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <b>2021</b> , 13,		2
105	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 4603-4638	5.6	3
104	An Update on Hepatocellular Carcinoma in Chronic Kidney Disease. <b>2021</b> , 13,		1
103	Chronic kidney disease. <i>Lancet, The</i> , <b>2021</b> , 398, 786-802	40	73
102	A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir + Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir + Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection. <b>2021</b> , 12, 640317		0
101	Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting. <b>2021</b> , 7, e761		1
100	Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C. <i>International Journal of Medical Informatics</i> , <b>2021</b> , 154, 104562	5.3	2
99	Elbasvir and grazoprevir for the treatment of hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 19, 1071-1081	5.5	0
98	Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 438-446	2.2	2

97	While direct-acting antivirals are effective, are there any unique safety considerations?. <b>2020</b> , 97-105		1
96	Prevention of Hepatitis C Virus Infection and Liver Cancer. <i>Recent Results in Cancer Research</i> , <b>2021</b> , 217, 107-140	1.5	2
95	Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 75, 857-867	7.4	15
94	Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 1424-1431	2.2	5
93	Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158431	3.7	74
92	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir + ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192627	3.7	5
91	Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194329	3.7	8
90	Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. <i>Journal of Clinical and Translational Hepatology</i> , <b>2017</b> , 5, 23-26	5.2	14
89	Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents. <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 322-335	5.2	2
88	COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS. <i>Arquivos De Gastroenterologia</i> , <b>2020</b> , 57, 39-44	1.3	4
87	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. <i>Oncotarget</i> , <b>2018</b> , 9, 16263-16270	3.3	3
86	C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, S12	3.2	6
85	Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, S13	3.2	1
84	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , <b>2019</b> , 58, 797-802	1.1	4
83	Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection. <i>Korean Journal of Clinical Pharmacy</i> , <b>2017</b> , 27, 150-160	0.2	1
82	KIDNEY DISEASE IN THE SETTING OF HIV INFECTION: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , <b>2018</b> , 22, 84-100	0.4	2
81	Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. <i>Clinical and Molecular Hepatology</i> , <b>2018</b> , 24, 351-357	6.9	0
80	Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. <i>Clinical and Molecular Hepatology</i> , <b>2018</b> , 24, 278-293	6.9	11

79	An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 400-407	6.9	3
78	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , <b>2020</b> , 25, 73-81	1.6	2
77	The new era of hepatitis C virus therapy. <i>Saudi Journal of Gastroenterology</i> , <b>2015</b> , 21, 345-54	3	2
76	SASLT guidelines: Update in treatment of Hepatitis C virus infection. <i>Saudi Journal of Gastroenterology</i> , <b>2016</b> , 22 Suppl, S25-57	3	15
75	Era of direct acting anti-viral agents for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 670-684	3.4	16
74	Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 833-839	3.4	10
73	Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. <i>Gut and Liver</i> , <b>2019</b> , 13, 191-196	4.8	1
72	MPGN and mixed cryoglobulinemia in a patient with hepatitis C - new treatment implications and renal outcomes. <i>Clinical Nephrology Case Studies</i> , <b>2017</b> , 5, 66-69	1.3	2
71	Hepatitis C and renal transplantation in era of new antiviral agents. <i>World Journal of Transplantation</i> , <b>2018</b> , 8, 84-96	2.3	4
70	Elbasvir/grazoprevir treatment in a hemodialysis patient with hepatitis C Virus Genotype 2a Infection, not responded to sofosbuvir/daclatasvir combination therapy. <i>Libyan Journal of Medical Sciences</i> , <b>2021</b> , 5, 132	0.1	
69	Therapie der Hepatitis C: Welche Problemkonstellationen gibt es noch?. <i>Gastroenterologe</i> , <b>2021</b> , 16, 442-451		
68	Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. <i>Journal of Medical Virology</i> , <b>2022</b> , 94, 675-682	19.7	0
67	Documento de informaci3n y consenso para la detecci3n y manejo de la enfermedad renal cr3nica. <i>Nefrologia</i> , <b>2021</b> ,	1.5	1
66	Management of hepatitis B and C in special population. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 6861-6873	5.6	0
65	. <i>Nihon Toseki Igakkai Zasshi</i> , <b>2016</b> , 49, 775-777	0.3	
64	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , <b>2016</b> , 4, 320-327	5.2	14
63	Treatment of hepatitis C virus infections in hemodialysis patients at our hospital and future prospects. <i>Nihon Toseki Igakkai Zasshi</i> , <b>2017</b> , 50, 281-287	0.3	
62	Elbasvir/grazoprevir. <i>Australian Prescriber</i> , <b>2017</b> , 40, 32-34	1.4	1



61	Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis. <i>Journal of Nephro pharmacology</i> , <b>2017</b> , 6, 49-61	0.8	0
60	IV. Treatment for Hepatitis or Liver Cirrhosis in Patients with CKD. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2017</b> , 106, 936-941	0	
59	. <b>2017</b> , 15,		
58	Transplantation of Kidneys from Hepatitis C Virus-Positive donors into uninfected recipients. <i>Indian Journal of Transplantation</i> , <b>2018</b> , 12, 159	0.2	
57	V. Current status and future of hepatitis C treatment, remaining problems. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2018</b> , 107, 38-43	0	
56	5. ??? . <i>Nihon Toseki Igakkai Zasshi</i> , <b>2018</b> , 51, 780-785	0.3	
55	Chronische Hepatitis. <b>2018</b> , 433-445		
54	History of Treatment for Hepatitis C - In the Era When Cure Is Achieved with Oral Drugs -. <i>Juntendo Medical Journal</i> , <b>2019</b> , 65, 2-11	0.1	
53	Prevention and Treatment of Viral Hepatitis. <b>2019</b> , 131-144		
52	Advances in Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , <b>2019</b> , 15, 106-114	0	
51	Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen. <i>Cureus</i> , <b>2019</b> , 11, e5702	1.2	1
50	Treatment of chronic hepatitis C in 2019. <i>Interni Medicina Pro Praxi</i> , <b>2019</b> , 21, 206-211	0	
49	Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 415-423	2.2	1
48	An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	0
47	Analysis of hepatitis virus infections among outpatients on chronic hemodialysis. <i>Nihon Toseki Igakkai Zasshi</i> , <b>2020</b> , 53, 139-145	0.3	
46	Management of hepatitis C patients with kidney failure. <i>Ortadoü Tıp Dergisi</i> , <b>2019</b> , 11, 577-584	0.1	
45	Kidney disease in patients with chronic liver disease. <i>Journal of the Korean Medical Association</i> , <b>2020</b> , 63, 14	0.5	
44	Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis. <i>Antiviral Therapy</i> , <b>2020</b> , 25, 305-314	1.6	1



43	Major Advances in Hepatitis C Treatment but Not Hepatitis B. <b>2020</b> , 103-129		
42	Should My Patient Accept a Kidney from a Hepatitis C Virus-Infected Donor?. <i>Kidney360</i> , <b>2020</b> , 1, 127-129.8	0	
41	Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring?. <b>2020</b> , 48-53		
40	More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 489-491	6.9	0
39	Glomerular Disease in Patients with Acute and Chronic Infections. <i>Nephrology Self-assessment Program: NephSAP</i> , <b>2020</b> , 19, 99-109	0	
38	New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , <b>2015</b> , 11, 458-66	0.7	11
37	50th International Liver Congress: update on viral hepatitis: 22-26 April 2015, Vienna, Austria. <i>Journal of Virus Eradication</i> , <b>2015</b> , 1, 227	2.8	
36	The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations. <i>Gastroenterology and Hepatology</i> , <b>2016</b> , 12, 1-11	0.7	5
35	Hepatitis C in a New Era: A Review of Current Therapies. <i>P and T</i> , <b>2017</b> , 42, 316-329	1.4	28
34	A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting [October 20-24, 2017 [Washington, DC]Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated	0.7	14
33	Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant vir Recipients. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 280-285 <i>gy</i> , <b>2017</b> , 13, 1-24	0.7	3
32	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 687-705	0.7	1
31	Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). <i>European Journal of Gastroenterology and Hepatology</i> , <b>2022</b> , 34, 76-83	2.2	1
30	Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2022</b> , 1-9	3.7	0
29	Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 79	4	1
28	A Convenient Synthesis of Fluoroalkylated Benzimidazole- or Indole-fused Benzoxazines. <i>European Journal of Organic Chemistry</i> , <b>2022</b> , 2022,	3.2	1
27	A waste to energy technology for Enrichment of biomethane generation: A review on operating parameters, types of biodigesters, solar assisted heating systems, socio economic benefits and challenges.. <i>Chemosphere</i> , <b>2022</b> , 293, 133486	8.4	3
26	Hepatitis C: Standard of Treatment and What to Do for Global Elimination.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	0

25	Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection.. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , AAC0200321	5.9	0
24	The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.. <i>Clinical and Experimental Medicine</i> , <b>2022</b> , 1	4.9	1
23	Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (≥5 years old): A Systematic Review and Meta-Analysis.. <i>Journal of Viral Hepatitis</i> , <b>2022</b> ,	3.4	
22	The curing regimens of HCV: A SWOT analysis.. <i>Antiviral Therapy</i> , <b>2022</b> , 27, 13596535211072672	1.6	0
21	Revolution in the diagnosis and management of hepatitis C virus infection in current era. <i>World Journal of Hepatology</i> , <b>2022</b> , 14, 647-669	3.4	0
20	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	5
19	Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study. <i>The Egyptian Journal of Internal Medicine</i> , <b>2022</b> , 34,	0.5	
18	Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 1-3	3.7	
17	Information and consensus document for the detection and management of chronic kidney disease. <b>2022</b> ,		0
16	Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.		0
15	Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. 1-12		0
14	Hepatitis C. <b>2022</b> ,		0
13	Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection. <b>2022</b> , 12, 2282		1
12	The art of managing hepatitis C virus in special population groups: a paradigm shift. <b>2022</b> , 12,		0
11	KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. <b>2022</b> , 102, S129-S205		1
10	A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD. <b>2022</b> ,		0
9	An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir/grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study). <b>2023</b> , 6,		0
8	Welcome to the Real World: Hepatitis C Virus Clinical Trials to Patient Realities. 32-40		0

- 7 Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. **2023**, 100899
- 6 Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
- 5 Glomerular Disease in Patients with Acute and Chronic Infections. **2022**, 21, 383-393
- 4 Treatment Recommendations for Harder-to-Cure and Vulnerable Populations. **2023**, 203-230
- 3 Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. 29, 949-966
- 2 Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study. **2023**, 7, e0031-e0031
- 1 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection. **2023**, 12, 2020